GlassScriptPhysician profile
Kristen Morrow
NPI 1245670801
$2,397.60
in general payments reported to CMS, 2019-2025
26 companies · $820 in 2025
The $820 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.90 · 2022: $527 · 2023: $290 · 2024: $681 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,790.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $409.66 | 2022-2025 | |
| Lilly USA, LLC | $236.66 | 2021-2024 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $235.74 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $213.56 | 2022-2025 | Caplyta |
| Pfizer INC. | $199.84 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $190.21 | 2024-2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.24 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $116.53 | 2022-2024 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $80.23 | 2022-2024 | Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $69.30 | 2025 | Auvelity |
| Alkermes, INC. | $65.86 | 2023-2025 | Lybalvi, Aristada |
| Amgen INC. | $50.28 | 2021-2025 | Evenity, Prolia |
| Exact Sciences Corporation | $48.44 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $47.64 | 2024-2025 | Cobenfy |
| Novo Nordisk INC | $44.24 | 2021-2025 | Wegovy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $33.45 | 2024 | Veozah |
| Collegium Pharmaceutical, INC. | $30.27 | 2025 | Jornay Pm |
| Mylan Specialty L.P. | $23.97 | 2023 | Yupelri |
| Corium, LLC | $22.16 | 2024-2025 | Azstarys |
| Medtronic, INC. | $19.54 | 2025 | Minimed 780g |
| Abbott Laboratories | $18.42 | 2022 | |
| Biomarin Pharmaceutical INC. | $18.40 | 2025 | Voxzogo 1.2mg |
| Ironshore Pharmaceuticals INC. | $16.45 | 2024 | |
| Idorsia Pharmaceuticals US INC | $14.41 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.94 | 2022 | |
| Dexcom, INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.